SCILEX TO PRESENT AT AEGIS CAPITAL HEALTHCARE & TECHNOLOGY CONFERENCE
MALVERN, PA. September 10, 2014 /PRNewswire/ — SCILEX Pharmaceuticals Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that it will participate in the upcoming Aegis Capital 2014 Healthcare & Technology Conference to be held at The Encore At Wynn in Las Vegas. The management of the Company will present at 8:30 a.m. on September 11, 2014.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, is an emerging specialty pharmaceutical company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain. The Company’s vision is to become a world-class, global pharmaceutical company that delivers the next generation of innovative products. Leveraging its network of global relationships, the Company seeks to acquire high barrier-to-entry, late-stage products for development and commercialization. The Company’s first product under development, Ztlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com
For more information contact Will Pedranti:
SCILEX Pharmaceuticals, Inc.
William Pedranti
484.875.3032
wpedranti@scilexpharma.com
0r
Jane Searle
MBS Value Partners, LLC
212.710.9686
jane.searle@mbsvalue.com
